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Endometrial cancer is the seventh frequent type of cancer among women. Identification 
of new prognostic markers is important to optimize treatment and follow-up of all EC 
patients. Understanding the molecular mechanisms of carcinogenesis may pave through 
discovery of further EC molecular markers.  
 
Cohort studies often disregard the individual features of tumors. Since such features may 
represent an opportunity to individualize cancer treatment, an innovative approach for 
their assessment should be developed. In this study (paper I), we addresses the 
previously overlooked individual characteristics of endometrial cancers, which could 
serve as a wellspring of information regarding specific molecular processes; regulators 
of such processes could potentially be useful for predicting aggression in individual 
endometrial tumors. Systemic analysis of individual proteome profiles represented that 
different proteins may be impacted in the individual endometrial tumors of different 
patients, but the impact of these proteins on basic cell functions may still be similar. 
The correlation between publically available gene expression data sets of profiling of 
endometrial tumors and our proteome profiling supports the conclusion that individual 
tumor features are doubtlessly crucial in endometrial tumorigenesis and are not 
inconsistent individual variations. IHC validation using tissue microarray analysis of 
MST1 and PKN1 proteins suggested their potential to serve as predictive biomarkers for 
endometrial cancer as well as efficacy of this approach.  
 
Transforming growth factor-β (TGFβ) and epidermal growth factor (EGF) are two potent 
regulators of tumorigenesis. Signaling cross-talk between TGFβ and EGF involves a 
number of regulators which define the impact on cell physiology (Paper II and III). In 
paper II, we discuss mammalian sterile-like 1 kinase (MST1) as a negative regulator of 
combined TGFβ and EGF signaling. We observed that enhanced expression of MST1 
inhibited the combined action of TGFβ1 and EGF on cell invasiveness, migration and 
proliferation. Monitoring of the intracellular regulatory proteins showed that the MST1 
contribution to TGFβ-EGF cross-talk may involve focal adhesion kinase and E-cadherin, 
but not activation of Smad2. Our data elucidated the negative feedback role of MST1 on 
TGFβ1-and EGF-regulated cell invasiveness, migration and proliferation. 
 
Our results from paper III demonstrated that protein kinase N1 (PKN1) modulated 
responses of HEC-A-1 endometrial cancer cells to TGFβ1 and EGF. PKN1 had an 
inhibitory effect on stimulation of cell migration, and PKN1 kinase activity was required 
for the inhibitory effect of TGFβ and EGF on cell proliferation and invasiveness. We 
observed that phosphorylation of Smad2, FAK and Erk1/2 correlated with cellular 
response to TGFβ1 and EGF. PKN1 modulates TGFβ and EGF-dependent regulation of 
cell proliferation, migration and invasiveness, and is therefore a component of the 
signaling network downstream of TGFβ and EGF. 
 
Thus, our findings provided insights into different mechanisms of tumorigenesis and on 
the impact of cross-talk between signaling pathways on tumor development.  
 
 
LIST OF PUBLICATIONS 
I.   
Attarha S, Andersson S, Mints M, Souchelnytskyi S*. Individualised 
proteome profiling of human endometrial tumours improves detection 
of new prognostic markers. Br J Cancer. 2013 Aug 6;109(3):704-13.  
 
II.   
Attarha S, Andersson S, Mints M*, Souchelnytskyi S*. Mammalian 
sterile-like 1 kinase inhibits TGFβ and EGF‑ dependent regulation of 
invasiveness, migration and proliferation of HEC-1-A endometrial 
cancer cells. Int J Oncol. 2014 Aug;45(2):853-60.  
 
III.   
Attarha S, Kanth R, Andersson S, Mints M*, Souchelnytskyi S*. PKN1 
modulates TGF-β and EGF signaling in HEC-1-A endometrial cancer 





IV.   
Kanth R, Attarha S, Santos CM, Kolakowska J, Funa K*, Souchelnytskyi 
S*. Proteomics of dedifferentiation of SK-N-BE2 neuroblastoma cells. 
(Under revision Cancer Science)  
 
V.  Santos C, Attarha S, Kanth R, Costa J, Barral-Netto M, Brodskyn CI*, 
Souchelnytskyi S*. Proteome profiling of Human Cutaneous 
Leishmaniasis lesion. (Accepted to J Invest Dermatol.) 
 
VI.  Nikoshkov A, Broliden K, Attarha S, Sviatoha V, Hellström A.C,  Mints M, 
Andersson S*. Expression pattern of the PRDX2, RAB1A, RAB1B, 
RAB5A and RAB25 genes in normal and cancer cervical tissues. 
(Accepted to Int J Oncol) 
 
VII.  Attarha S*, Mints M, Andersson S, Souchelnytskyi S. Endometrial cancer 
and application of proteomics. Exp Oncol. 2011 Sep;33(3):174-7 
 




1 Introduction ................................................................................................ 1 
1.1 ENDOMETRIAL CANCER ........................................................... 1 
1.1.1 Types of Endometrial cancer .............................................. 1 
1.1.2 Endometrial Cancer Detection and Treatment ................ 2 
1.1.3 Endometrial Tumorigenesis ................................................ 2 
1.2 TGF-β SIGNALING ........................................................................ 9 
1.2.1 TGF-β signaling and endometrial cancer ......................... 9 
1.3 TUMOUR BIOMARKERS .......................................................... 12 
1.3.1 Personalized medicine ....................................................... 12 
1.4 PROTEOMICS IN CANCER STUDIES .................................... 13 
1.4.1 General concept .................................................................. 13 
1.4.2 Clinical proteomics ............................................................ 14 
1.4.3 Systems and network analysis .......................................... 18 
2 Present Study ............................................................................................ 20 
2.1 Aims .................................................................................................. 20 
2.2 Materials and methods................................................................... 21 
2.2.1 Materials .............................................................................. 21 
2.2.2 Tissue sample preparation ................................................ 21 
2.2.3 Two-dimensional gel electrophoresis ............................... 21 
2.2.4 Gel image analysis .............................................................. 21 
2.2.5 Mass spectrometry ............................................................. 21 
2.2.6 Systematic analysis ............................................................. 22 
2.2.7 Immunohistochemistry ...................................................... 22 
2.2.8 Immunoblotting .................................................................. 22 
2.2.9 Construct and transfection ............................................... 23 
2.2.10 Cell Culture ......................................................................... 23 
2.2.11 Cell proliferation assay ...................................................... 23 
2.2.12 Cell apoptosis assay ............................................................ 23 
2.2.13 Wound healing assay ......................................................... 23 
2.2.14 Migration assay .................................................................. 24 
2.2.15 Invasion assay ..................................................................... 24 
2.2.16 Statistical analysis .............................................................. 24 
2.3 Results and Discussion ................................................................... 25 
2.3.1 Paper 1 ................................................................................. 25 
2.3.2 Paper 2 ................................................................................. 30 
2.3.3 Paper 3 ................................................................................. 34 
3 General conclusions ................................................................................. 38 
4 Acknowledgements ................................................................................... 39 







2DE 2 dimensional gel electrophoresis 




Protein Kinase B 
ALK 
BSA 
activin receptor-like kinase 
Bovine serum albumin 
Cdc42 cell division cycle 42  
CDKN2A cyclin-dependent kinase inhibitor 2A 
CT 
DTT 
Computed tomography  
dithiothreitol 




epidermal growth factor 
EMT epithelial to mesenchymal transition 
ERBB2 erythroblastic leukemia viral oncogene homolog 2 
ERK 
FBS 
extracellular signal-regulated protein kinases 
fetal bovine serum  
FAK Focal adhesion kinase 
FGFR2 fibroblast growth factor receptor 2 
FOXO1 forkhead box O1 
FOXO3 forkhead box O3 
GO gene ontology 
GTPase guanosine triphosphate hydrolase 
IEF isoelectric focusing 
IHC immunohistochemistry 
JAK Janus kinase 
JNK c-Jun N-terminal kinase 
LAP latency-associated peptide 
LC  liquid chromatography 
LTBP latent TGFβ-binding protein 
L-TGF-β latent-transforming growth factor beta 
MALDI-TOF matrix-assisted laser desorption/ionization time-of-flight 
MAPK mitogen-activated protein kinase 
MMPs matrix metallopeptidases 
MRI Magnetic resonance imaging 
MS mass spectrometry 
MST1 Mammalian sterile-like 1 kinase 
mTOR Mammalian target of rapamycin 
NF-kB nuclear factor kappa B 
PAK1 p21 protein-activated kinase 1 
Para6 
PBS 
ParA domain protein 
Phosphate-buffered saline  
 
 
PDK1 pyruvate dehydrogenase kinase 
PET Positron emission tomography 
pI isoelectric point 
PI3K phosphatidylinositol 3-OH kinase 
PKA Protein kinase A 
PKN1 
POD 
protein kinase N1 
peroxidase  
PTEN phosphatase and tensin homolog deleted from chromosome 10 
PTM post-translational modification 
RAC1 
Ras 
ras-related C3 botulinum toxin substrate 1 
retrovirus-associated DNA sequences  
Rb Retinoblastoma 
RhoA ras homolog family member A 
R-Smad activin receptor-like kinase 
S100A4 S100 calcium binding protein A4 
SAPK 
SDS 
stress-activated protein kinase 
Sodium dodecyl sulfate 
ShcA type III chaperone protein ShcA 
Smad SMA-related, mothers against decapentaplegic protein 
SNP Single-nucleotide polymorphism 
TGF-β transforming growth factor beta 
TGF-βR transforming growth factor-β receptor 
TP53 
TMA 
tumor protein p53 







1.1 ENDOMETRIAL CANCER  
Endometrial cancer (EC) is the seventh frequent type of cancer among women and 
the most common malignancy of the female reproductive system, accounting for 6% 
of all female cancers in industrialized countries and carries a 2-3% lifetime risk for 
acquiring the disease (Salvesen et al, 2012)(Engelsen et al, 2009)(Attarha et al, 
2011).The incidence of endometrial cancer is estimated at 15-20 per 100,000 women 
per year, which translates to 81,500 new cases each year (Martinho et al, 
2012)(Dedes et al, 2011). The exact etiology of endometrial cancer remains 
unknown. The disease is uncommon before age 40, with <20% occurring before 
menopause (Engelsen et al, 2009).  
1.1.1 Types of Endometrial cancer 
Most endometrial cancers (90%) are adenocarcinomas that arise from uterine 
epithelial cells (Kim et al, 2010). All endometrial carcinomas are categorized into two 
groups depending on histopathology, each displaying a clear association with 
molecular findings (Muinelo-Romay et al, 2011). Low-grade, early-stage, highly 
differentiated estrogen-related endometrioid adenocarcinomas (Type I) account for 
more than 80% of cases, and usually have a good prognosis. Endometrial hyperplasia 
in the setting of excess oestrogen exposure gives rise to endometrioid 
adenocarcinoma, which usually affects pre- and perimenopausal women (Mhawech-
Fauceglia et al, 2012)(Engelsen et al, 2008)(Kim et al, 2010)(Martinho et al, 2012). 
Non-endometrioid (Type II) tumors (papillary serous and clear cell tumors) are not 
estrogen-related and show a 3–10% variable prevalence among all endometrial 
carcinomas; typically, these are high-grade tumors that are poorly differentiated and 
highly invasive in the myometrium, showing a more aggressive clinical course 
(Mhawech-Fauceglia et al, 2012)(Engelsen et al, 2008)(Martinho et al, 2012). These 
tumors usually affect older postmenopausal women with atrophic non-neoplastic 
endometrium (Kim et al, 2010)(Attarha et al, 2011).  
 
One third of all cases who die from this disease were initially diagnosed with early-
stage disease (Trovik et al, 2011). Early appearance of symptoms allows diagnosis at 
an early stage when the disease is still restricted to the uterus, and is associated with a 
high rate of survival (Dizon, 2010). However, a subset of endometrial tumors which 
display aggressive behavior characterized by high histological grade, as well as by 
lymphovascular and myometrial invasion, is associated with poor prognosis. In about 
25% of cases, surgical staging revealed extrauterine disease (Muinelo-Romay et al, 
2011).  
 
Invasion and metastatic spread are necessary for cancer progression. Metastatic 
disease represents an advanced stage of most cancers (Mannelqvist et al, 2011). The 
primary sites affected by early development of endometrial cancer include the adnexa 
and pelvic viscera, as well as the pelvic and paraaortic lymph nodes; a low incidence 
of distant metastases occurs through hematogenous spread. The molecular 
mechanisms underlying aggressive transformation and dissemination are largely 
 2 
 
unknown (Muinelo-Romay et al, 2011). Patients with aggressive disease who are at 
risk of recurrence receive adjuvant treatment after surgery. Although these patients 
initially show a good response to localized tumor surgery, they often succumb to 
metastatic disease associated with a reduction in overall survival (Abal et al, 2007).  
1.1.2 Endometrial Cancer Detection and Treatment  
Despite the growing body of knowledge that points to a unique distinction between 
type I and type II endometrial cancers, the current basis for management of EC 
involves various surgical procedures (complete hysterectomy, bilateral salpingo-
oophorectomy) and surgical staging. Patients with more aggressive disease who are at 
high risk of recurrence are treated with additional surgical intervention including 
omentectomy, as well as para-aortic and pelvic lymphadenectomy. Adjuvant therapy 
is necessary in this group of patients. Regardless of the type of endometrial 
carcinoma, postoperative treatment includes radiation therapy and chemotherapy 
regimens that provide similar benefit in both types (Dedes et al, 2011)(Trovik et al, 
2012)(Lambropoulou et al, 2010)(Frederick & Straughn, 2009). Of all endometrial 
cancers, many occur in older women with co-morbidity, obesity and a high risk of 
complications in response to aggressive treatment (Dizon, 2010).  
 
Therefore the ultimate goal is to find the best treatment for women with endometrial 
cancer, while avoiding overtreatment or undertreatment. However, the risk associated 
with individual patients can usually be determined postoperatively. Due to limitations 
imposed by pathological factors preoperatively or intraoperatively, selection of 
patients appropriate for lymphadenectomy is difficult. Preoperative histological 
assessment of endometrial biopsy often differs from the final pathology reading 
(Goudge et al, 2004). Imaging procedures such as MRI, CT and PET are limited in 
terms of both specificity and sensitivity in their ability to define the extent of 
myometrial invasion and lymph node metastasis, as well as cervical and parametrial 
involvement.   
 
Specific therapies targeting each type of endometrial cancer have not yet been 
introduced. Thus there is a need to individualize type-specific therapy in order to 
avoid unnecessary surgical and adjuvant treatment and their associated side effects 
(Engelsen et al, 2009). Identification of new prognostic markers is important to 
optimize treatment and follow-up of all EC patients (Mannelqvist et al, 2009).  
1.1.3 Endometrial Tumorigenesis  
1.1.3.1  Molecular mechanism of endometrial tumorigenesis  
The molecular mechanism underlying endometrial carcinoma has not yet been fully 
explored. Differences in molecular alterations distinguish the types of endometrial 
carcinomas. Type I tumors are diploid, microsatellite-unstable, frequently hormone-
receptor positive and demonstrate dysregulation of the PI3K/PTEN/AKT molecular 
pathway with loss of PTEN gene functionality, oncogenic mutations, and 
overexpression of upstream tyrosine kinase growth factor receptors, causing 
uncontrolled cell survival and proliferation. Type II tumors are often  aneuploid, more 
common among older women and demonstrate alterations in CDKN2A, TP53, and 
 3 
 
ERBB2 (Salvesen et al, 2012), as well as loss of E-cadherin expression, and 




Figure 1. A model for progression of endometrial carcinoma associated with a higher 
number of chromosomal abnormalities in endometrioid lesions than in hyperplasia, presence 
of genetic alterations in atypical hyperplasia and elevated levels of these in well-
differentiated carcinomas compared with atypical hyperplasia. Reprinted from Doll et al., 
Journal of Steroid Biochemistry & Molecular Biology 2008, with permission from Elsevier 
(Doll et al, 2008). 
 
1.1.3.2  In vitro models of endometrial cancer 
Most in vitro models pertaining to human endometrial epithelial cells were developed 
by injecting fragments of tumor or specific numbers of cells into fat pads of isogenic 
animals, specifically athymic nude mice or rats (Vollmer, 2003).   
  
Two factors affecting the invasive properties of endometrial cancer cells in vitro are 
cell lines origin and level of differentiation. Among the most commonly studied cell 
lines, SNG-M (metastatic lymph node derived cell line) and NUE-1 (poorly-
differentiated cancer cell line) are classified to be more invasive compared to      
HEC-1BE and HEC-1A (moderately-differentiated) or HEC-6 and Ishikawa        
(well-differentiated) cell lines (Mori et al, 1994).  
 
The first endometrial cancer cell line, HEC-1 (human endometrial cancer-1), was 
generated in May 16, 1968 by culturing uterus tissue extract of a woman with grade 2 
endometrial cancer. Initially, for selection of epithelial cell type, a plasma clot culture 
was created; expanded cells were cultured over 3 generations and subsequently 
placed into monolayer culture. The HEC-1-A monolayer cell culture demonstrated 
steady, continuous logarithmic growth with 2 terminated cases of normal endometrial 
cells between 100 and 150 days. HEC-1 cell population doubling time was estimated 




Many proteins were shown to have a strong impact on the invasiveness of 
endometrial cancer. Non-invasive cell lines transfected with such regulators can also 
serve as an in vitro model for invasiveness. One example is the S100A4 model, in 
which endometrial cancer cell lines are transfected with S100A4, which mediates 
cancer invasion and serves as a target of TGF-β1 signaling (Xie et al, 2009).  
 
Further effort is required to explore the underlying mechanism of endometrial cancer 
invasiveness and aggressiveness, which could provide greater insight of both 
diagnostic and therapeutic importance.  
1.1.3.3 Molecular mechanism of cancer invasion  
Endometrial cancer invasion is a complex biological process involving a series of 
cellular events in which E-cadherin down-regulation is a key component of the EMT 
process, along with alterations of other cell-cell contact molecules that affect the 
migratory properties of cells. Moreover, other modified transcription factors and 
signaling pathways affect the ability of cancer cells to invade the myometrium, and 
are involved in changes in histological grade and metastatic potential (Figure 2)(Abal 




Figure 2. Crucial molecular events in progression of endometrial cancer invasion. Reprinted 
from Abal et al., Clinical and Translational Oncology 2007, with permission from Springer 
(Abal et al, 2007). 
 
 
The invasive nature of cancer is a complicated  biological process which involves  
modifications in cell motility and adhesion that enables tumor cells to bind to and 
migrate through the extracellular matrix (ECM) and to invade the basal layer of 
connective tissue (Oh et al, 2009). Some of these alterations develop at cell/ECM 
contact points known as focal adhesions, which consist of membrane-associated, and 
cytoskeletal components, ECM proteins, as well as intracellular signaling molecules. 
One of these putative signaling molecules is a protein tyrosine kinase called FAK 
(Focal adhesion kinase)(Owens et al, 1995). 
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Several factors, including G protein-coupled receptors, integrin receptors and Src 
activate FAK. Integrins are transmembrane receptors that transmit growth factor 
signals by means of contact with the extracellular matrix. Autophosphorylation of 
tyrosine Y397 FAK is a key regulator of integrin signals in cancer cells. 
Overexpression of FAK has been investigated in several human cancers, including 
colorectal, head and neck (HNSCC), breast, sarcoma, prostate, and thyroid, and 
correlates with survival outcomes (Thanapprapasr, 2011)(McLean et al, 2005).  The 
role of FAK kinases has been widely studied in cell survival (Tamura et al, 1999), 
migration (Turecková et al, 2009), invasion (Siesser & Hanks, 2006) and tumor 




Figure 3. Schematic representation of how FAK is involved in cancer progression. FAK 
induces the invasive pathway by downstream signalling to regulators such as JUN N-
terminal kinase (JNK) and RAC1, as well as to matrix metalloproteinases (MMPs). FAK acts 
as a key downstream effector of growth-factor-receptor and integrin signalling inhibiting 
apoptosis and taking part in cell growth via the RAS–MAPK (mitogen-activated protein 
kinase) pathway. Reprinted from McLean et al., Nature Reviews Cancer 2005, with 
permission from Nature Publishing Group (McLean et al, 2005). 
 
 
Epithelial-derived cancers can progress to an invasive, metastatic state, which 
correlates with a change from an adherent, epithelial nature into a motile, fibroblast-
like morphology, an epithelial to mesenchymal transition (EMT)(Peinado et al, 
2007). Mesenchymal cells are defined by three major characteristics in their cellular 
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phenotype and their behavior (Figure 4): (1) loss of strong adhesive epithelial cell–
cell contacts and (2) the acquisition of a spread, spindle-shaped morphology with 
markers from cell–cell junction proteins, i.e., E-cadherin and cytokeratin intermediate 
filaments (specific to epithelial cells) to vimentin filaments and fibronectin, and (3) 
increased motility that facilitates invasion through the extracellular matrix. These 
changes are not necessarily observable during the EMT process, although single cell 
acquisition of the ability to migrate and invade the extracellular matrixe is considered 
a functional hallmark of EMT (Colas et al, 2012).  
 
Further research is required to elucidate the details surrounding the mechanism of cancer 
invasion and key regulators of this process in order to develop drug targets to block 
invasive-specific pathways. Since proteins are typically the targets for diagnosis and 
treatment of cancer, it is anticipated that proteomics analysis of such proteins will 




Figure 4. Basic steps in epithelial to mesenchymal transition (EMT), along with the main 
steps associated with progression of EMT and MET, involved in regulation of adherents and 
tight junctions. Reprinted from Thiery & Sleeman, Nature Reviews Molecular Cell Biology 
2006, with permission from Nature Publishing Group (Thiery & Sleeman, 2006). 
 
1.1.3.4 MST1 in endometrial cancer tumorigenesis  
Mammalian Sterile-like 1 (MST1) is a serine/threonine kinase belonging to the Sterile 
20-like superfamily, and has been described to be a stress-activated protein involved 
in a various apoptotic responses (Creasy & Chernoff, 1995)(Minoo et al, 2007). It has 
been identified as a proapoptotic cytoplasmic kinase which comprises a catalytic 
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domain at the N-terminal, an autoinhibitory region, a dimerization domain and a non-
catalytic domain with a nuclear localization motif at the C-terminal (Ng et al, 
2013)(Creasy et al, 1996). When cleaved in the autoinhibitory region, MST1 
amplifies the apoptotic signals and produces an extremely active catalytic portion. 
This process is mediated by cleavage of the caspase-3-recognition motif located 
between the regulatory and catalytic regions (Minoo et al, 2007). The cleaved MST1 
passes into the nucleus, where it stimulates chromatin condensation through 
phosphorylation of histone 2B at Ser14 and thereby apoptosis (Yuan et al, 
2010)(Praskova et al, 2004). MST1 involvement in cell death has also been 
demonstrated via phosphorylation of FOXO3a-Ser207 and the corresponding site of 
FOXO1-Ser212 (Lehtinen et al, 2006). Other studies have shown that overexpression 
of MST1 alone can initiate apoptosis via pathways involving activation of SAPK 
/Jnk, p53, and perhaps other effectors as well(Graves et al, 1998)(Lin et al, 
2002)(Praskova et al, 2004). 
 
Phosphorylation of MST1 seems to be essential for regulation of its activity. In the 
MST1 structure, several phosphorylation sites are located on the threonine residue 
and have been shown to positively or negatively regulate MST1 activity (Collak et al, 
2012). Phosphorylation of Thr183 and Thr187 within the N-terminal MST1 activation 
loop is a crucial molecular event for the activation of MST1 and for cell death  in 
mammalian cells and results in a catalytically more active nuclear form of MST1-N 
(Minoo et al, 2007)(Collak et al, 2012).   
 
In addition to its proapoptotic function, MST1 has been shown to be a key factor in 
cell-cycle progression, tumorigenesis and mammalian development (Cinar et al, 
2011). Reduced or lost MST1 expression has been seen in HNSCC (Steinmann et al, 
2009), soft tissue sarcoma (Seidel et al, 2007), glioblastoma (Qiao et al, 2010), and 
colorectal cancers (Minoo et al, 2007), and is accompanied by a worse prognosis 
(Seidel et al, 2007). Other in vivo studies suggest that conditional ablation of MST1 
results in liver enlargement (Song et al, 2010). Although a lot has been discovered of 
the role of MST1 in tumorigenesis MST1 activity in other signaling pathways and in 
the regulation of invasiveness of endometrial cancer cells remains relatively 
unexplored.    
1.1.3.5 PKN1 in endometrial cancer tumorigenesis  
PKN1 (protein kinase N1) also known as PAK1 is a serine/threonine kinase which 
contain three highly conserved regions: (i) a regulatory domain in the N terminal (ii) a 
catalytically active part located in the C terminal similar to protein kinase C (PKC) 
(iii) an area referred to as the D region located between the regulatory and catalytic 
domains (Metzger et al, 2003)(Takahashi et al, 1998). The N-terminal domain 
function is crucial for activation of PKN1 (Takahashi et al, 1998) by providing the 
PKN1 activation loop, which is important for serine/threonine kinase activity and the 
regions required for interaction with other factors participating in the signaling 
pathway of PKN1, such as Ro GTPases that bind to the hydrophobic region of PKN1 
in the N-terminal (Galgano et al, 2009).  
 
Development of the metastatic phenotype requires enhanced cell motility and 
invasiveness, which necessitates cytoskeletal reorganization. Cdc42, Rac1, and RhoA 
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small GTPases regulate these processes. Although the exact mechanism of regulation 
of cytoskeletal changes by GTPases has yet to be clarified, it does involve protein 
kinase N1 (PKN1) activation (Carter et al, 2004). Once activated, PKN1 facilitates 
downstream signaling actions involved in apoptosis, transformation, cell motility and 
reorganization of the cytoskeleton. Additional signaling molecules such as JAK2, 
PDK1 and PKA can also affect PKN1 activity. Diverse signals activate PKN1, 
resulting in  autophosphorylation of numerous sites such as Thr423, which is located 
in the auto-inhibitory loop of the kinase (Liu et al, 2009). PKN1 also activates 
various signaling pathways, as well as p38 MAPK, JNK, NF-kB and ERKs 
(Vadlamudi et al, 2000). 
 
Kinase-dead mutant of PKN1 inhibits the invasive ability of human breast cancer cell 
lines (Adam et al, 2000), as well as breast epithelial cell migration in response to 
heregulin (Adam et al, 1998). It also inhibits ras-mediated transformation of rat 
Schwann cells (Tang et al, 1998). In rat fibroblasts, PKN1 activation is required for 
transformation of cells by Rho, Ras, and Rac (Tang et al, 1999). PKN1 induces the 
polarized extension of the actin cytoskeleton in the developing neurite of PC12 cells 
and also known as a target of downstream network signaling of Rho family GTPases 
(Daniels et al, 1998). Transfection of constitutively active PKN1 in HeLa cells and 
fibroblasts leads to disintegration of stress fibers and reconstitution of focal structures 
(Manser et al, 1997). Expression of wild-type, constitutively active or kinase-dead 
PKN1 in NIH 3T3 cells shows substantial differences in actin organization. 
Expression of constitutively active PKN1 in fibroblasts causes formation of huge 
polarized lamellipodia at the leading edge that enhance motility and exhibit greater 
directional movement (Sells et al, 1999). 
 
Separate from the explained functions, PKN1 transgenic overexpression in the 
mammary gland stimulates malignant and premalignant lesion formation in animal 
models, though with extended latency. Such research is helping to clarify the possible 
role of PKN1 in tumorigenesis (Ong et al, 2011). PKN1 overexpression has been 
reported to have an association with prostate, colorectal and aggressive ovarian 
cancers (Carter et al, 2004)(Metzger et al, 2003)(Galgano et al, 2009). Further studies 
suggested, PKN1 may also influence the invasive characteristics of breast and gastric 
cancer cells (Adam et al, 2000)(Liu et al, 2009). Regardless of findings in elucidation 
of PKN1 function in tumorigenesis, the relevant downstream pathways of PKN1 and 
its involvement in other signaling pathways and regulation of the invasiveness of 














1.2 TGF-β SIGNALING  
1.2.1  TGF-β signaling and endometrial cancer 
Transforming growth factor-β (TGF-β), cytokine belongs to TGF-β superfamily has 
three distinct isoforms including TGF-β1, β2 and β3. Secreted TGF-β is biologically 
inactive and is referred to as the latent form, L-TGF-β. Biologically active TGF-β 
forms upon cleavage of the pro-form and dissociation of active TGF-β from latency-
conferring proteins, latent TGF-β binding protein (LTBP) and latency-associated 
peptide (LAP)(Massagué et al, 2000).  
 
Once activated by dimerization, TGF-β mediates signaling pathway using the TGF-β 
type I (TGF-βRI) and type II (TGF-βRII) receptors. Following binding of TGF-β 
ligand to TGF-βRII and formation of a heterotetrameric complex with TGF-βRI, 
TGF-βRI will become phosphorylated by TGF-βRII. However, the TGF-βRI known 
as activin receptor-like kinase 5 (ALK5), mediates signaling responses in most type 
of cells; other type of TGF-βRI, such as ALK1, also transduce signals in specific cell 
types. TGF-βRIs phosphorylate receptor-regulated Smad (R-Smad) proteins for 
mediating signals: Smad3 and Smad2 proteins by ALK5 and Smad1, Smad5, and 
Smad8 proteins by ALK1. Upon activation, Smad proteins build a complex with 
other Smad protein family members referred to as common Smad (co-Smad) and 
known as Smad4, then move into the nucleus where they mediate activation or 
repression of transcription of target genes. Other DNA-binding transcription factors 
assist Smad complexes in regulating high affinity interaction and specificity (Figure 
5)(Meulmeester & Ten Dijke, 2011).  
 
TGF-β mediates its signaling through other signaling pathways known as non Smad-
dependent TGF-β pathways. There are several alternative TGF-β signaling pathways that 
do not involve Smad proteins, including phosphoinositol-3 kinase (PI3K), mitogen-
activated protein kinases (MAPKs), and Rho-like GTPase. Activation of these pathways 
is stimulated by non-Smad substrates for either type of TGF-β receptors and further 
receptor-interacting proteins, such as Par6 and ShcA, that are phosphorylated straight by 
TGF-β receptor kinases (Mu et al, 2012)(Lee et al, 2007)(Ozdamar et al, 2005). 
 
TGF-β performs a pivotal function in body growth during embryogenesis and in 
tissue homeostasis. Regulation of such biological processes is mediated by TGF-β 
signaling, which controls adhesion, invasion, differentiation, proliferation and 
apoptosis (Heldin et al, 2009). TGF-β functions as a molecule with double role in 
carcinogenesis. In early-stage cancer, TGF-β has a tumor suppressor role, causing 
growth inhibition, apoptosis and cell cycle arrest, but in advanced-stage cancer, TGF-
β instead promotes tumorigenesis. Cancer cells lose their normal response to TGF-β 
and develop atypical TGF-β signaling, which  promotes cell proliferation, survival, 






Figure 5. TGF-β intracellular signaling. After TGF-β ligand binding and formation of a 
heterotetrameric complex of TGF-βRI and TGF-βRII, R-Smads become phosphorylated by 
activated TGF-βRI. Phosphorylated R-Smads, principally Smad3 and Smad2, binds to Co-
Smad (Smad4) and shift to the nucleus and mediate activation or repression of transcription 
of the ideal gene in cooperation with further DNA-binding transcription factors. The 
activated TGF-β receptor complex also mediates signals through activation of other 
pathways such as PI3K and MAPKs. TGF-β can inhibit the kinase activity of S6 through 
activation of phosphatase PP2A. However, the molecular details relating to these processes 
have yet to be explored. Reprinted from Wakefield & Roberts, Current Opinion in Genetics & 
Development 2002, with permission from Elsevier (Wakefield & Roberts, 2002). 
 
 
It has been proposed that TGF-β family members inhibit epithelial cell proliferation 
and actively participate in neoplastic transformation of human endometrium. Previous 
studies have suggested that expression of TGF-β isoforms may vary as preneoplastic 
complex hyperplasia evolves into endometrial carcinoma (Piestrzeniewicz-Ulanska et 
al, 2008). TGF-β has been reported as a paracrine regulator of proliferative activity in 
human endometrial cells; alterations in the level of expression can promote neoplastic 
transformation of endometrium (Albright & Kaufman, 1995). Such alterations are not 
just limited to decreased TGF-β mRNA levels in non-neoplastic tissues compared 
with endometrial cancer, but also  entail variations in expression patterns of specific 




Alterations in expression level of all three TGF-β isoforms, specifically a substantial 
increase during the transition from normal proliferative endometrium to simple or 
complex hyperplasia were prominently observed in the glandular epithelium (Gold et 
al, 1994). However, progression of preneoplastic complex hyperplasia to endometrial 
carcinoma was not accompanied by any further changes in TGF-β expression. While 
the level of TGF-β isoform protein expression remained constant in stromal cells, the 
mRNA expression level increased significantly in stromal cells of complex 
hyperplasia (Gold et al, 1994). These studies propose that one of the early molecular 
events during neoplastic transformation of endometrium is activation and 
dysregulation of expression of TGF-β isoforms at either mRNA or protein levels. 
Dysregulation of the LTBP expression, which is required for TGF-β secretion and 
proper folding, is also likely to occur, though this has to be yet investigated 
(Piestrzeniewicz-Ulanska et al, 2008). 
 
Although mutations of TGF-β receptor gene are less frequent in endometrial 
carcinomas  but such mutations were frequently observed in pancreatic, head and 
neck and colorectal cancers (Kim et al, 2000). Analysis by Nakashima et al. found 
that 2.6% of sporadic human endometrial tumors show alterations in the TGF-βRI 
kinase domain of the gene, while 17% of the analyzed tumors demonstrated sequence 
changes in the TGF-βRII gene (Nakashima et al, 1999).  
 
It has been reported that variations in TGF-βRII affect endometrial cancer 
progression (Myeroff et al, 1995)(Piestrzeniewicz-Ulanska et al, 2004)(Ohwada et al, 
2000)(Sakaguchi et al, 2005). Although down-regulation of TGF-β receptors is a 
well-accepted common characteristic of endometrial cancers, there are still 
conflicting studies which use different experimental techniques and control groups 
(Parekh et al, 2002)(Piestrzeniewicz-Ulanska et al, 2002)(Sakaguchi et al, 2005). It 
has been revealed that TGF-βRII expression is elevated in endometrial cancers with 
myometrial infiltration, compared with non-infiltrating endometrial cancers  
(Piestrzeniewicz-Ulanska et al, 2004), implying that elevated TGF-βRII expression 
stimulates local invasion and metastasis (Wakefield & Roberts, 2002)(Derynck et al, 

















1.3 TUMOUR BIOMARKERS 
Cancer is a heterogeneous disease. Efforts to detect cancer at an early stage have 
prompted physicians and researchers to develop the concept of biomarker 
identification (Paul et al, 2013). Tumor biomarkers are measurable molecular 
indicators that are produced in the tumor or other body tissues and fluids in response 
to the presence of cancer (Tainsky, 2009).  
 
Biomarkers are biological analytes such as nucleic acids (SNPs, chromosome 
aberrations, DNA copy number changes, differential promoter-region methylation, 
over- or underexpressed RNA transcripts and regulatory RNAs), proteins (tumor 
antigens, cell-surface receptors or peptides released into body fluids), lipids, 
metabolites or biological properties, such as angiogenesis, proliferation, apoptosis, 
oxygen tension, or clinical characteristics that can be quantitatively measured as 
indicators of biological processes or therapeutic response in cancer patients (Ludwig 
& Weinstein, 2005)(Mishra & Verma, 2010). 
 
An ideal tumor biomarker should have high analytical specificity and sensitivity, and 
be easily, reliably and cost-effectively measurable in a noninvasive or minimally 
invasive manner (Mäbert et al, 2014). Potential biomarkers must overcome several 
obstacles to be considered for routine clinical use. Biomarkers should be developed in 
5 phases: preclinical investigation, clinical assay and validation, retrospective 
longitudinal and prospective screening and cancer control (Pepe et al, 2001).  
 
There are currently several candidate biomarkers to distinguish endometrial tumors, 
although none are applied in daily clinical routines (Salvesen et al, 2012). Recently, 
studies have reported a few promising prognostic biomarkers, including tumor 
suppressor P53 (Engelsen et al, 2006)(Salvesen et al, 1999), DNA ploidy (Pradhan et 
al, 2012)(Susini et al, 2007) and progesterone and oestrogen receptors (Creasman, 
1993)(Kauppila et al, 1986). The majority of such research has involved retrospective 
analysis of patients who were not subjected to histological subtyping, diagnostic 
imaging or lymph node biopsy (Salvesen et al, 2012). As a result of molecular 
profiling of primary tumor tissues, several encouraging targets for drug development, 
such as the FGFR2 and PI3K/PTEN/AKT/mTOR pathway, have been reported 
(Westin & Broaddus, 2012)(Salvesen et al, 2012)(Dedes et al, 2011). Thus, such 
proteins can be used as a companion to help make a diagnosis and select drugs. 
 
1.3.1 Personalized medicine    
Heterogeneity in histological appearance, molecular regulatory mechanisms and 
cellular composition has been found among individual cancer patients (Tian et al, 
2012)(Saunders et al, 2012). Such irregularity results in diverse responses and poses a 
major drawback to efficacious cancer treatment. A limited response to cancer 
treatment may entail removal or destruction of some tumor cells, while the tumor may 
then be repopulated by resistant cells (Saunders et al, 2012).  
 
One approach that is gaining momentum for the treatment of various diseases, 
especially cancer, is personalized medicine (Lin et al, 2012). Utilization of different 
approaches, including genomics, transcriptomics, proteomics and metabolomics, 
generates a huge quantity of data that may result in the introduction of novel 
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biomarkers for various purposes. Consequently, further exploration of such studies 
could be important for the integration of personalized medicine into standard clinical 
practice and therapy (Lin et al, 2012).  
 
Due to inter-patient and intra-tumor variability, the response to any given treatment 
strategy may vary from one individual to another. Compared with cohort-based 
studies, molecular profiling of tumors for each patient may become a more effective 
strategy for cancer management. Personalized treatment aims to maximize treatment 
benefit for patients while minimizing toxicity and excessive risk, as well as to provide 
optimal prevention and follow up (Dancik & Theodorescu, 2012). Due to the rapid 
increase in the number of publications addressing personalized cancer treatment in 
recent years (Attarha et al, 2013)(Zakharchenko et al, 2010), treatment of endometrial 
cancer is also highly likely to benefit from these novel approaches which are quickly 
gaining momentum (Westin & Broaddus, 2012).  
1.4 PROTEOMICS IN CANCER STUDIES  
1.4.1 General concept  
The word “proteome” was originally coined by Wilkins in 1996 (Wilkins et al, 1996). 
“Proteome” refers to the complete complement of proteins translated by a genome 
which provides information about 1) translation of expressed gene products 2) the 
quantities of proteins produced by the gene and 3) the level of posttranslational 
modification (Humphery-Smith & Blackstock, 1997).  
  
Proteomics is a powerful tool that allows for broad, simultaneous investigation of 
proteins in complex biological structures and is intended for the evaluation of their 
expression, function, interactions, structure, modifications and localization. The 
nature of proteomics enables detection of key pathways for cellular responses to 
microenvironmental changes by revealing alterations among cellular signaling 
pathways (Maxwell et al, 2011)(Meehan et al, 2010)(Creutzberg et al, 2000). In 
addition to the power of proteomics for analysis of  the abundance of proteins and 
their PTMs, this tool has been useful in numerous fields of  science, as well as for 
drug target discovery and identification of novel diagnostic biomarkers (Boja et al, 
2011).  
 
Subjecting complex biological systems to analysis by proteomics is quickly 
producing a wealth of ‘omics’-scale data requiring additional investigation. The key 
companion strategy to address these accumulating data is systems biology. Systemic 
analysis is an effective approach at systems level for investigating the profound 
nature of biological structures and for visualization of these data to translate them into 
clear and  meaningful biological knowledge (Gehlenborg et al, 2010)(Kitano, 2002). 
Incorporation of proteomic and genomic technologies in combination with cutting-
edge bioinformatic tools makes it possible to simultaneously analyze thousands of 
biological molecules. These techniques allow discovery of novel tumor signatures 
with enough sensitivity and specificity for early stage detection of cancer, monitoring 
of disease progression and selection of appropriate treatment, while also paving the 




1.4.2 Clinical proteomics  
Clinical proteomics studies are designed for clinical and analytical validation and 
application of novel biomarkers for disease treatment and diagnosis, as well as to 
incorporate the selection, validation, and assessment of the most appropriate and 
powerful techniques, with the potential for integration with existing analytical 
platform workflows in clinical laboratories. “Top down” and “bottom up” proteomics 
are alternative approaches for allocation of targets with potential use in clinical 
proteomics. In the “top down” proteomics method, unbiased potential targets can be 
identified by applying high-throughput techniques to cohort or population-based 
groups and then further analyzed for function, specificity and sensitivity. In the 
“Bottom up” method, potential targets are selected based on protein–protein or 
metabolite interaction in known pathways with the aim of identification of extra 
targets with better stability, sensitivity and specificity (Apweiler et al, 2009). 
Although technological advances in clinical proteomics provide great potential for 
detection of the causes of cancer, prediction of patient risk for developing specific 
cancer types, prediction of disease outcome, and guidance for choice of treatment, 
there are still enormous obstacles to overcome based on previous studies on the 
clinical application of proteomics (Breuer & Murph, 2011).  
 
The three major factors in proteomics studies are selection of technique for proteins 
separation, visualization of separated proteins and their precise identification, 
possibly followed by exploration of post translational modifications (PTMs) and use 
of bioinformatics for data analysis (Stein & Zvelebil, 2002). Based on different 
approaches, proteomics include “gel-based” and shotgun proteomics. Mass 
spectrometry is the preferred approach for protein or peptide identification and 
characterization (Kolker et al., 2006). A recent advance involves the addition of 
antibody-based methodology to proteomics. This approach includes application of 
immunohistochemical analysis (IHC) to tissue microarrays (TMAs), using of 
antibody arrays for serum-based diagnostic assays and using of reverse phase protein 
arrays (RPPAs) for pathway analysis (Borrebaeck & Wingren, 2007)(Wingren & 
Borrebaeck, 2004)(Brennan et al, 2010).   
1.4.2.1 Gel-based proteomics 
Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) or two- 
dimensional electrophoresis (2DE) is the most common methodology in this approach 
and is one of the cornerstone techniques in proteomics. Proteins are separated based 
on their isoelectric point (1st dimension, isoelectric focusing or IEF) and their 
molecular weight (2nd dimension, MW). 2DE is known to be an accepted and 
powerful technique for proteins separation, followed by protein visualization using 
Coomassie blue or silver staining. Regardless of the relatively higher sensitivity for 
detection of proteins in gels, almost all silver techniques have a limited dynamic 
range (Figure 6)(O’Farrell, 1975).  
 
A fairly recent development within this technique that was introduced by Unlü et al. 
in 1997 allows differential labeling of various protein samples and separates them on 
the same gel. In this technology, referred to as differential in-gel electrophoresis 
(DIGE), protein samples are labeled with fluorescent dyes (cyanine dyes or CyDyes) 
prior to two-dimensional electrophoresis. The greatest benefit of the DIGE technique 
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is the application of the same strategy to biological samples, which decreases 
experimental variations and generates distinct 2DE images from the same gel (Unlü et 




Figure 6. Representative image of 2D gels generated with the proteins extracted from the 
cancer and healthy adjacent tissue. Proteins are separated based on their isoelectric point 
(1st dimension) and their molecular weight (2nd dimension). 
 
 
In order to process the information from the 2DE-gel, translation of gel information 
into digital data is required. Depending on the staining method, this is carried out 
using an appropriate imaging system, such as laser-based detectors, CCD cameras or 
flatbed scanners. Translation of complex data into appropriate biological information 
is carried out using computerized data analysis provided by software packages 
developed for this scope.    
1.4.2.2 Protein identification using Mass Spectrometry  
For most proteomic strategies, mass spectrometry (MS) appears to be an optimal 
technique for protein identification. Molecular mass of a charged particle is measured 
by MS by calculating its mass-to-charge (m/z) ratio. In general, mass spectrum is 
obtained by plotting (m/z) ratio vs. ion abundance (Paul et al, 2013).  
 
Basic components of a mass spectrometer are represented in Table 1. Since 
explanation of the fundamental concepts underlying all available MS technology is 
beyond the scope of this thesis, we will focus solely on the technique used in our 
studies: matrix assisted laser desorption ionization-time-of-flight MS (MALDI-TOF-




Sample Introduction Ionization Source Mass Analyzer Ion Detector 
• GC Column 
• HPLC Column 
• Solid probe 
• Electron ionization 
• Fast atom 
bombardment 
• Laser desorption 
• Electrospray 
• Time-Of-Flight 
• Ion trap  
• Quadrupole 
• Magnetic sector 
• Ion Cyclotron 
Resonance and 
Fourier transform 
•  Orbitrap 
• Electron multiplier 
• Scintillation counter  
 
 




Matrix-assisted laser desorption ionization (MALDI) term was invented in 1985 by 
Hillenkamp and Karas (Karas et al, 1985). It has been recognized as a useful source 
for generation of intact gas-phase ions from a wide array of compounds, including 
proteins. Ionization by MALDI is achieved by dissolving a protein compound in a 
solvent, containing in solution crystalline structure of small, organic and UV-
absorbing molecules i.e. matrix. Matrix crystals can absorb laser wavelengths similar 
to those used for ionization of the protein or peptide. Upon UV laser beam irradiation, 
the matrix crystals become heated through accretion of considerable energy, which 
excites them and causes analyte ions to pass into a gas phase where they become 
protonated (acquisition of H+) and are accelerated by an electric field into the mass 
analyzer. Although the most frequent ions detected by MALDI are (M+H+), in the 
case of large proteins additional signals for multiply charged ions and oligomeric 
forms of the analyte have also been detected (Karas & Hillenkamp, 1988)(Figure 7).   
 
The mechanism of ion formation in time-of-flight (TOF) mass analyzers involves 
pulsed ionization in the existence of an electric field in a short source region. The 
electric field accelerates the ions into a long field-free drift region. Based on 
molecular mass, the flying time for the ions to traverse the drift region (TOF) is 
altered. This process is defined by the relationship: E=1/2mv2, where E is kinetic 
energy, m is mass of the ion and v is the ion velocity. At a constant energy, ions with 
higher molecular mass will travel at lower speed, thus have longer time-of-flight than 
lighter ones. The TOF of the MALDI ions is measured using a clock triggered by a 
laser pulse. All ions formed from a single laser pulse that are accelerated by the 
electric field give rise to a transient TOF signal from the detector at the end of the 






Figure 7. Matrix-assisted laser desorption/ionization (MALDI) source. Pulsed UV beam 
targeting the analyte matrix co-crystal drives desorption, followed by desolvation and 
transfer into the mass analyzer. Reprinted from Kicman AT, Parkin MC, Iles RK, Molecular 
and Cellular Endocrinology 2007, with permission from Elsevier (Kicman et al, 2007). 
 
 
Poor mass resolution was a major weakness of the ﬁrst TOF analyzers. Several 
factors that disrupt time of flight of ions with similar mass-to-charge ratio affect final 
mass resolution. These factors are the kinetic energy distribution, space distribution 
and time distribution. This issue was significantly overcome with the development of 
two techniques: 1) delayed pulsed extraction, which introduces a time lag or delay 
among ion formation in the source field-free region and extraction of ions outside the 
source by a voltage pulse and 2) The reﬂectron functions as an ion mirror by turning 
and directing the ions back through the ﬂight tube (de Hoffmann & Stroobant, 2007). 
The resulting “spectrum” is the output of the detector, where the y axis corresponds to 
the ions abundance at a specific point in time (signal intensity) and the x axis 
represents the “mass-to-charge” ratio (size)(Figure 8).   
 
MALDI-TOF-MS has the advantage of tolerating small quantities of contaminants 
and has the capacity to analyze small quantities of proteins. MALDI data can be 
further examined by submitting the data to an automatic database search. The peptide 
mass fingerprint (PMF) resulting from proteolytic digestion of gel-excised proteins 
and their mass analysis can be further investigated using protein databases for 






Figure 8. Schematic representation of MALDI-TOF mass spectrometer. Irradiation of a laser 
beam induces the matrix to become excited which causes analyte ions on the matrix to pass 
into a gas phase. The existing electric field accelerates the ions into a long field-free drift 
region. Initial ion energy differences are corrected by reflection of ions in an ion mirror. The 
detector contains an electron multiplier.  With similar kinetic energy in the TOF analyzer, the 
travel time of ions will be (m/z) ratio of them. URef, ion mirror and reflection voltage, Uvar, 
applied pulsed to delayed extraction, Uacc, acceleration voltag. Reprinted from Mann et al., 




1.4.2.3 Gel-free shotgun proteomics 
“Bottom-up” proteomics analysis, characterizes proteins by analyzing peptides using 
proteolysis. The term shotgun proteomics was coined by the Yates Lab and refers to 
the application of bottom-up proteomics analysis to protein mixtures, thereby 
indirectly measuring proteins by analyzing the peptides generated from proteolysis of 
intact proteins. Typically, the peptide mixture in shotgun proteomics analysis is 
initially fragmented, and then accompanied by liquid chromatography, which is 
joined to tandem mass spectrometry (LC-MS/MS) for further analysis. In shotgun 
proteomics, peptides are identified by contrasting tandem mass spectra of fragmented 
peptides with deposited theoretical tandem mass spectra available in protein 
databases. Peptide sequences are referenced with proteins to infer the protein 
molecules. The identified proteins are classified and scored depending on their 
peptides, since individually, they may refer to one protein or to more than one protein 
(Zhang et al, 2013). The advance represented by this technique made it possible to 
avoid some of the limitations of gel-based proteomics, including the requirement for a 
large amount of material, limited dynamic range, low-throughput analysis, difficulties 
in the identification of acidic, basic, hydrophobic, very small or very large proteins 
and bias toward abundant proteins (Mäbert et al, 2014)(Walther & Mann, 2010).  
 
1.4.3 Systems and network analysis  
The complex interactions between elements of biological systems, including DNAs, 
proteins and metabolites, directly affect activities of such biological entities. 
Previously, the signaling pathway approach was the only source of knowledge 
regarding interaction between these components. Exploration of the intricate nature of 
biological systems involves emergence of several signaling pathways into a higher-
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order biological network. The main approach to accomplish this is application of 
systems and network analysis tools (Lin et al, 2012). Acquiring perceptive view of 
biology at the a system level requires not only evaluation of single cells or part of an 
organism, but investigation of the structure and dynamics of cellular and organismal 
function as well (Kitano, 2002).  
 
Recently, promising findings have emerged from several proteomics and genomics 
studies confirming the effective role of system and network analysis in the exploration 
of complicated biological systems. These tools make it possible to carry out global 
mapping of organelles or cells, as well as to find out, conceptualize and analyze the 
complex function of relevant biological systems. Moreover, analysis of the functional 
and topological aspects of these networks can help elucidate the cellular regulatory 
mechanisms responsible for environmental changes (Kwoh & Ng, 2007)(Lin et al, 
2012).    
 
Interaction networks are built using nodes in various shapes representing genes, 
proteins, and metabolites, as well as edges representing biological connections 
(activation, induction, inhibition, PTM, enzymatic-substrate reaction, physical binding) 
between nodes. The vast majority of biological networks have the characteristic of 
scale-free network in which a few nodes have the highest number of connections 
(hubs), while the remainder have just a few connections (Barabási & Oltvai, 2004).   
 
Several tools are available for building and analyzing interaction networks (Gehlenborg 
et al, 2010), such as Cytoscape (Cline et al, 2007) and Osprey (Breitkreutz et al, 2003), 
as well as pathway analysis tools such as PathVisio (van Iersel et al, 2008) and 
BioTapestry (Longabaugh et al, 2009). Each of these tools has unique functions and 
can be used in both genomics and proteomics analysis. The preferred tool for our 
studies was Cytoscape.  
 
Briefly, Cytoscape is a free tool that 1) incorporates proteomics data into a network 2) 
edits and visualizes the network and 3) analyzes networks using external plug-ins. 
Graphing tools such as MiMi were used to construct the proteomics data network (Gao 
et al, 2009). Nodes and edges can be selected based on various principles, as well as by 
attribute or name (Shannon et al, 2003). One strong reason for choosing Cytoscape for 
proteomics analysis is the function that allows use of diverse external plug-ins for 
systemic analysis.  The plug-ins used for systemic analysis in this study are described 
below. MCODE is an external plug-in used to extract network modules, representing 
extremely connected regions or clusters in the biological network (Bader & Hogue, 
2003). NetworkAnalyzer is a plug-in that calculates various factors related to network 
topology such as number of connected components and other complex factors, 
including betweenness centrality and closeness centrality. Knowledge about these 
parameters enables further investigation of biological properties of the network, 
including protein-protein interaction and signalling networks (Assenov et al, 2008). 
Centiscape is another topology analysis plug-in that calculates the indexes of centrality 
for each node and their relationship within the network, which facilitates identification 





2 Present Study 
2.1 Aims 
The general aims of this project are to expand current knowledge about the proteome 
changes in Endometrial Cancer (EC) with respect to the malignant potential of EC, to 
identify proteins that are relevant to EC carcinogenesis and to describe potential 
marker protein patterns that could aid in the diagnosis, evaluation and prognosis of 
EC.   
 
The specific aims for each paper are described as below:  
 
I. To generate individualized proteome profiles of endometrial tumors to serve 
as a source of information about the affected molecular processes and to 
identify key regulators and prognostic signatures of endometrial cancer 
aggressiveness    
 
II. To explore the involvement of MST1 in regulation of invasiveness of 
endometrial cancer cells and its contribution to TGF-β and EGF signaling 
 
III. To study the role of PKN1 in invasiveness of endometrial cancer cells and 
























2.2 Materials and methods 
2.2.1 Materials  
Our studies used cultured endometrial cell lines (HEC-1-A, KLE) and human 
endometrial cancer biopsies. We collected clinical samples at the Department of 
Women’s and Children’s Health, Karolinska University Hospital (Stockholm, 
Sweden), after being granted ethical Permit 2006/649. All materials were obtained at 
the time of surgery and put on ice prior to processing by a pathologist. The 
endometrial epithelial tissue samples for the proteomics analysis were stored at           
-70°C. The sections intended for immunohistopathological diagnostics were obtained 
at the Department of Oncology-Pathology, Karolinska University Hospital (Sweden). 
2.2.2  Tissue sample preparation 
Samples for use in the proteomics study were directly extracted in 2D-GE rehydration 
buffer (2% CHAPS, 0.5% ampholytes, 8 M urea, 0.002% Bromophenol blue, 0.28% 
DTT, IPG buffer, pH 3-10) and mechanically disintegrated at room temperature using 
glass beads. We used the supernatants from tissue extracts that were centrifuged for 
15 min at 13,000 rpm for 2D-GE.  
2.2.3 Two-dimensional gel electrophoresis                                          
We carried out 2D-GE in two steps. We used an IPGPhor unit (GE Healthcare, 
Uppsala, Sweden) to conduct IEF as follows: 20 μA per strip, rehydration at 50 V; 3 
hrs, 1000 V; 1 hrs, 5000 V; 10 hrs, or until 32,000 Vhrs was reached. Following IEF, 
we equilibrated IPG strips in 2 stages using equilibration buffer (1.5 M Tris-Hcl, pH 
8.8, 30% glycerol, 2% SDS, 6 M urea, 0.002% Bromophenol blue) with 1% DTT for 
10 min in first stage, and with 2.5% iodoacetamide for 10 min in the second. We 
conducted second dimension SDS-PAGE using an Ettan Dalt Six electrophoresis 
system (GE Healthcare, Uppsala, Sweden) as follows: 0.5 W per gel for 15 min, 1 W 
per gel for 30 min, and 10 W per gel until the run was completed. For each sample, 
we produced two 12% gels. Proteins were detected using 0.25% silver nitrate.  
2.2.4 Gel image analysis 
Stained gels were scanned and the spots were analyzed by tool embedded in the dedicated 
software Image Master Platinum v6.0 (GE Healthcare, Uppsala, Sweden). We ensured 
the statistical significance (p<0.05) of the spot selection using the Student’s t-test 
embedded in the software. Proteins that demonstrated either a > twofold change in 
expression pattern, or that exhibited a unique pattern of expression between the tumor 
and adjacent histologically normal tissue for each pair of cancer/non-cancer tissue 
samples were considered for mass spectrometry identification.  
2.2.5 Mass spectrometry  
After excision of protein spots from gels they were destained and digested in-gel with 
trypsin (modified sequence-grade, porcine, Promega, Madison, WI, USA) as 
described earlier (Attarha et al, 2013). We desalted and concentrated tryptic peptides 
on a μC18 ZipTip (Millipore Billerica, MA, USA). Fifty percent acetonitrile, with a 
matrix α-Cyano-4-hydroxycinnamic acid was used to elute peptides onto the MS 
target and subsequently analyzed using a MALDI-TOF Reflectron (Waters, Milford, 
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USA). We processed the mass spectra using Micromass software (MassLynx™ 
Software v4.0). Autolytic peptides produced from exposure to trypsin (842.510, 
1045.564 and 2211.105 Da) were used for internal calibration of peptide spectra. For 
protein identification, the ProFound search engine 
(http://65.219.84.5/service/prowl/profounf.html) was used to search the NCBI nr 
sequence database. Partial oxidation of methionine, alkylation with iodoacetamide 
and one missed cleavage were acceptable. We limited the search parameters for Mr 
and pI by comparing the migration position of protein in generated gels and a mass 
tolerance of less than 0.1. The species search was set to “Homo sapiens.” Z-value, 
sequence coverage, mass precision and probability value of the matched peptides 
were used to evaluate the significance of the identified proteins.  
2.2.6 Systematic analysis 
We converted the protein names into GO terminology 
(http://biodbnet.abcc.ncifcrf.gov/). The data were subjected to systematic analysis 
using Cytoscape and GoMiner (http://discover.nci.nih.gov/gominer/) software. 
Identified proteins were classified into biologically coherent categories and assessed 
by GoMiner. Cytoscape was used to explore relationships between the identified 
proteins. Analysis was conducted by generating a network using the proteins we 
identified, the MiMIplugin, along with all available databases. We viewed the 
network in Cytoscape; the Network analysis plugin was used to calculate 
betweenness, after which the AllegroMCODE plugin was used to extract network 
modules. When determining network connectivity we used Fisher’s exact test for 
calculating p-value.  
2.2.7 Immunohistochemistry 
Expression of targeted proteins was evaluated using IHC analysis of EMC1021 
(Pantomics Inc., Richmond, CA, USA) and UT501 USBiomax (US Biomax Inc., 
Rockville, MD, USA) EC arrays as described earlier (Attarha et al, 2013). Of the 50 
cases on the UT501 array, 5 cases were normal, 2 were serous adenocarcinoma, 41 
cases were endometrioid adenocarcinoma and 2 were representing clear cell 
adenocarcinoma. The other array included 97 cases of EC along with 5 cases of 
normal tissue. Arrays were stained with target primary antibodies at dilution 
recommended by the manufacturer. DakoCytomation Target Retrieval Solution, High 
pH (DAKO, Carpinteria, CA, USA) was used for antigen retrieval. We stained the 
sections with VECTASTAIN Elite ABC kits (Vector Laboratories Inc., Burlingame, 
CA, USA), then counterstained using hematoxylin, after which we mounted using 
Fluoromount G (Southern Biotechnology, Birmingham, AL). We photographed and 
analyzed the slides with a Leica DFC camera and embedded software Leica QWin 
Standard (Leica Microsystems Imaging Solutions Ltd, Cambridge, UK). 
2.2.8 Immunoblotting  
We resolved cell lysates on 10% SDS polyacrylamide mini-gels and subsequently 
transferred them to nitrocellulose membranes (Whatman, protran, Dassel, Germany), 
then blocked the membranes with 5% Bovine serum albumin (BSA) and incubated 
with primary antibodies using, the dilution specified by the supplier, and culminated 
the process by incubating with HRP-conjugated secondary antibody (GE Healthcare, 
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Uppsala, Sweden). Luminol Reagents (Santa Cruz Biotechnology Inc.) were used for 
protein visualization.    
2.2.9 Construct and transfection  
Drs. Hideyuki Mukai and Zengqiang Yuan kindly provided us with expression 
constructs for targeted proteins. HEC-1-A cells in 12-well plates were transfected 
with GeneJuice® transfection reagent, in accordance with the manufacturer’s 
recommendations (Novagen, Darmstadt, Germany), in order to generate stable 
transfected cell lines. Following transfection for 48 hours, we transferred the cells 
onto a 10-cm petri dish and subjected them to selection for 3 weeks using 200µg/ml 
of G418. The single colonies we picked up were culture-expanded for 4 weeks. 
Immunoblotting with specific antibodies was used to validate protein expression 
within stable transfected cells.  Because the cells did not respond to identical 
transfection conditions or take up DNA following repeated passage, we chose to 
generate transiently transfected cell lines instead.   
2.2.10  Cell Culture  
Our studies used the HEC-1-A and KLE cell lines, which were ordered from ATCC 
(Manassas, VA). Selection of a media for cell culture was based on the manufacturer 
recommendation, supplemented with 10% FBS.  
 
2.2.11 Cell proliferation assay  
We measured proliferation activity of cells with the CellTiter 96® AQueous One 
Solution Cell proliferation assay (Promega, Promega Biotech AB, Stockholm, 
Sweden). The assay performed in accordance with the recommendations of the 
manufacturer. McCoy’s 5A Medium Modified supplemented with 1% 
penicillin/streptomycin and 10% FBS was used to grow the cells.   
 
2.2.12 Cell apoptosis assay                                                         
The Cell Death Detection ELISAPlus (Roche, Germany) was used to assess cell 
apoptosis. We placed cell lysates on a streptavidin-coated microplate and 
supplemented it with a combined solution of anti-DNA-peroxidase (anti-DNA-POD) 
and anti-histone-biotin, followed by incubation at 25˚C for 2 hrs. Following the 
washing step and removal of unbound antibodies photometric determination of POD 
was carried out at 405 nm using ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-
sulphonic acid)) as substrate. 
2.2.13 Wound healing assay 
We grew cells in 10% FBS culture medium for 48 hours until they reached 
confluence. The confluent culture monolayers were lightly scratched using a 20 µl-
pipette tip, and images under light microscopy were obtained from the scratched 
areas. After incubation overnight, a new set of images of the scratched areas were 
obtained. TScratch software was used for quantification and involved measuring the 
open wound area, defined as the fraction of open area at the later time point compared 
with its earlier initial appearance, expressed as a percentage (Gebäck et al, 2009). 
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2.2.14 Migration assay 
We seeded the cells suspended in culture medium onto the well membranes of the 96-
well ChemoTx® chemotaxis system plate (cat. no. #116-8; Neuro Probe Inc.). After 
incubating for 24 h, we washed the membrane twice with PBS and used 70% ethanol 
as a fixative. A cotton swab was used to remove non-migrated cells from the upper 
side of the membrane, after which we stained the membrane with 0.5% crystal violet 
and used ImageJ software for visualization and quantification (Schneider et al, 2012).  
2.2.15 Invasion assay 
We seeded the cells suspended in culture medium onto the 3% gelatin-covered 
membranes of the 96-well plate of the ChemoTx chemotaxis system (cat. no. #116-8). 
Then, after 24 h, we washed the membranes two times in PBS and used 70% ethanol 
for fixation. A cotton swab was used to remove the non-invaded cells from the upper 
side of the membrane. Finally, we stained the membrane with 0.5% crystal violet, 
used ImageJ software for visualization and quantification (Schneider et al, 2012).  
2.2.16 Statistical analysis 
We used the Mann-Whitney test to evaluate statistical significance of differences 
observed in unpaired groups and the Kruskal-Wallis test followed by Dunn's Multiple 
Comparison Test for multiple groups. For statistical analysis we used Graph Prism 6 

























2.3 Results and Discussion  
2.3.1 Paper 1  
 
Individualized proteome profiling of human endometrial tumors improves 
detection of new prognostic markers 
 
Proteomic profiling of tumors may improve our ability to diagnose and treat cancer. 
Researchers often search for possible biomarkers by examining data shared by a 
multitude of patients, without concerning themselves about variations that may 
distinguish one patient from another. However, since major researches of human 
carcinogenesis have recently presented pronounced differences in tumor-related 
profiles among individuals (Saunders et al, 2012)(Tian et al, 2012), exploring 
personal tumor variables is crucial for a deeper comprehension of tumorigenesis, 
diagnosis and therapeutic choices. 
 
Concerns about making a diagnosis of endometrial cancer based on histopathology 
necessitate identification of additional biomarkers to describe the functional 
molecular profile of endometrial tumors. Despite numerous attempts, we have as yet 
been unable to identify any molecular biomarkers that reflect aggressive behavior of 
individual endometrial tumors (Salvesen et al, 2012). Recently, studies have reported 
a few promising prognostic biomarkers, including tumor suppressor P53 (Engelsen et 
al, 2006)(Salvesen et al, 1999), DNA ploidy (Pradhan et al, 2012)(Susini et al, 2007) 
and progesterone and oestrogen receptors (Creasman, 1993)(Kauppila et al, 1986). 
The majority of such research has involved retrospective analysis of patients who 
were not subjected to histological subtyping, diagnostic imaging or lymph node 
biopsy (Salvesen et al, 2012). As a result of molecular profiling of primary tumor 
tissues, several encouraging targets for drug development, such as the FGFR2 and 
PI3K/PTEN/AKT/mTOR pathway, have been reported (Westin & Broaddus, 
2012)(Salvesen et al, 2012)(Dedes et al, 2011). Thus, such proteins can be used as a 
companion to help make a diagnosis and select drugs. 
 
Regulatory proteins are less likely to be identified than high abundance proteins, 
since individual tumors display substantial variation. Traditionally, identification of 
tumor-specific changes involves listing the proteins that are universally expressed by 
all tumors, and then formulating a second list of proteins universal to cancer-free 
controls. A comparison of these lists reveals differences in protein profiles that may 
be interpreted to reflect significant cancer-specific changes. However, this strategy 
presumes that tumorigenesis proceeds along a common pathway, demonstrating 
identical changes in every case of cancer, but since tumors are heterogeneous, this 
strategy may overlook individually unique tumor profiles. Our study addresses the 
previously overlooked individual characteristics of endometrial cancers, which could 
serve as a wellspring of information regarding specific molecular processes; 
regulators of such processes could potentially be useful for predicting aggression in 




We used a two-component approach to assess how individual characteristics of 
endometrial tumors contribute to tumorigenesis. First we conducted proteome 
profiling for three separate cases. Next we carried out a meta-analysis of individual 
endometrial tumor characteristics, which served as a basis for finding potential 
biomarkers. The procedure also involved IHC validation of a separate set of EC 
cases. Because we concerned ourselves with the role of individual tumor 
characteristics, we had to confine ourselves to a given number of cases for the 
profiling portion of this study. To validate the markers chosen from our proteomics 
results, we conducted tissue microarray testing on a total of 168 EC and normal cases. 
Since we uncovered intact proteins in tumor sampling, we studied these instead of 
examining peptides that were produced artificially, as those used in peptide-based 
strategies with tandem mass spectrometry. Using 2D gel electrophoresis, we were 
able to identify over 2,000 intact proteins with their isoforms in each run. 
 
The three tumors demonstrated substantial variation in protein expression. We 
identified 298 tumor-related proteins in case one, and 121 and 165 tumor-related 
proteins in cases two and three, respectively. Considerable variation in tumor proteins 
was found when analyzing these three cases. For each tumor, we conducted molecular 
profiling on the proteins discovered during proteome profiling in order to uncover the 
implications of this variability.  
 
The identified proteins were used to construct networks for each case of endometrial 
carcinoma in order to map the molecular profiles of each tumor. Next we used our 
networks to pinpoint what signaling mechanisms were influenced in the tumors. 
Researchers have definitively shown that the various components of a specific 
signaling network are able to regulate important cell functions in an identical way 
(Souchelnytskyi, 2005). We postulate that various proteins may be impacted in the 
individual tumors of different patients, but the impact of these proteins on basic cell 
functions may still be similar. Consequently, we tested the concept that “many means 
lead to the same end” by studying the proteins that were uncovered on a case-by-case 
basis, and finished by subjecting individual datasets to meta-analysis in order to 
uncover shared mechanisms. 
 
Our initial task was to find out which of the identified proteins of a particular tumor 
impacted what functional domain. Next, we compared these functional domains 
related to each case among the three cases of endometrioid carcinoma. As anticipated, 
we found that functional domains overlapped significantly among these three cases of 
endometrioid cancer. Highly overlapping domains involve regulation of proliferation 
and cell growth, immune response, cell migration, hormonal response and control of 
angiogenesis. Overlap indicates similarities between the impacted tumor mechanisms. 
But, when analyzing individual network components, no overlap was found, 
suggesting that individual tumors employ different mechanisms to realize similar 
objectives, such as uncontrolled growth. This finding is significant for selection of 
cancer treatment. Different drugs can be used to target the unique properties of each 
tumor. In other words, a different drug may uniquely useful for each of our three 
cases—methotrexate in case one, salinomycin in case two, and trichostatin A in case 
three—which underscores how attention to individual tumor characteristics may be 




To confirm the usefulness of the proteins we identified and their signaling networks 
to serve as predictive biomarkers of individual tumor aggression, we expanded our 
focus to include both aggressive and non-aggressive signatures through extraction of 
common dependencies to the protein networks of these three cases, and for species 
stored in the Array Expression database of EBI. The correlation between gene 
expression data and proteome profiling that we noted is highly significant because it 
validates our own proteome profiling of only three cases, which discovered changes 
also found in our large-scale study. This encouraging finding underscores the need for 
further research on the proteins we identified here as biomarkers of endometrial 
cancer invasiveness and aggressiveness. 
 
We created interaction networks among proteins representing invasive and non-
invasive characteristic and the proteins and genes on which they may have an impact 
and the genes validated by analyzing published datasets to discover systemic 
properties of the signaling mechanisms of these proteins. We concentrated on 
invasiveness, because it is a prerequisite for tumor aggression. 
 
When addressing aggressive and non-aggressive tumor behavior, we anticipate that 
the main intersections among nodes of non-invasive and invasive networks could be 
essential regulators of aggressiveness. By analyzing node connectivity we found that 
ACTA1, ZBTB16, TAF1, HNF4A may serve as important regulators for the non-
aggressive network, while TAF1, HNF4A, JUN, ATF7IP, ATF2 were uncovered as 
possible aggressive network regulators.  
 
We chose PKN1 and MST1 to validate by tissue microarray. Our choice of these 
proteins was motivated by published data possibly implicating them in EC (Ng et al, 
2013)(Galgano et al, 2009). A validation study was conducted on the same cases that 
we subjected to proteome profiling and on other endometrial cancer cases and 
performed a tissue microarray on the endometrial cancer specimens. We subjected a 
total of 168 cases to analysis using two different tissue microarrays. We screened 
individual tumor profiles to pinpoint these two proteins and our validation study and 
confirm their potential as predictors of aggressive tumor behavior in endometrial 
cancer. 
 
The most important barrier to developing efficacious cancer therapy is the variability 
of molecular profiles displayed by different tumors. We pursued a strategy of 
subjecting three endometrioid carcinoma cases to complete proteomic profiling and 
systematic study in order to reveal the unique properties of each tumor. We then 
carried out meta-analysis of the individual profiles using the proteome profiling 
results for each tumor. Breast tumors have been profiled using similar strategies, 
which has significantly improved understanding of the mechanisms that are involved 
in tumorigenesis (Zakharchenko et al, 2010). Our validation study, based on 
immunohistochemistry, investigated a large cohort of cases and was able to confirm 
the utility of this strategy for the study of EC.  
 
Frequently observed features common to a number of cancers, including endometrial, 
are molecular regulatory mechanisms and cellular composition, as well as inter-
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patient and intra-tumor variability in histological appearance (Saunders et al, 
2012)(Tian et al, 2012). It is precisely such variability that creates a significant 
barrier to efficacious treatment for cancer. The high rate of incomplete treatment 
response can likely be attributed to partial clearing of tumor cells, which permits 
more resistant cells to rebuild the tumor (Saunders et al, 2012). Gene mutation and 
RNA expression studies are the principle tools of tumor molecular profiling 
(Kohlmann et al, 2012). However, endometrial cancer proteome profiling is on the 
rise and our data support the successful use of proteome studies to improve 
diagnostics. The combination of 2D-GE and MS has proven to be the best intact-
protein proteomics approach to investigating full-length proteins, thereby yielding a 
genuine protein-based profile (Wilkins et al, 2006).  
 
A combined approach using the various OMICs studies has been integral to achieving 
a significantly more complete overview of the mechanisms than any single 
technology could achieve (Koboldt D, 2012)(Tian et al, 2012). The optimal basis for 
formulating cancer diagnostics and therapy would be a combined approach using 
proteomics, metabolomics, transcriptomics, genome sequencing and clinical 
observations. The suitability of combining proteomics and transcriptomics has been 
demonstrated by our results, a combination that verifies the pertinence of our 
proteomics findings. Nevertheless, the need for more detailed protein ontology along 
with incomplete knowledge of genes from transcriptomic studies have resulted in 
missing data, which now poses a challenge (Lan et al, 2003). Systems biology tools 
may solve this problem in part, since they allow us to explore interdependencies 
among identified genes and proteins (Hucka et al, 2003). The most common strategy 
to explore such dependencies is to create a network, which is also helpful for 
predicting key regulators. Network topology provides us with a computer-assisted 
approach to help identify key functions and associated regulators, thereby improving 
quality and adding to the findings significance (Hucka et al, 2003). We were able to 
identify PKN1 and MST1 as possible endometrial tumorigenesis regulators by 
studying protein networks using Cytoscape and by combining mRNA expression 
profiles with proteomics data.   
 
The possible tumorigenic role of the PKN1 and MST1 kinases has already been 
demonstrated. MST1 has been demonstrated to promote growth of hepatocellular 
carcinoma in the presence of downregulation of NORE1B (Ng et al, 2013). Research 
has shown that loss of cytoplasmic MST1 expression is a tumor progression marker 
in colorectal cancer (Minoo et al, 2007). Research has correlated PKN1 upregulation 
with prostate, colorectal and aggressive ovarian cancers (Carter et al, 2004)(Metzger 
et al, 2003)(Galgano et al, 2009). Other research implicates PKN1 effect on the 
invasive characteristics of breast and gastric cancer cells (Adam et al, 2000)(Liu et al, 
2009). Although recent research has helped to elucidate the mechanisms by which 
PKN1 and MST1 are involved in tumorigenesis, we have yet to investigate the role of 
these proteins in progression and development of EC. The potential of PKN1 and 
MST1 to serve as potential predictive biomarkers of EC, with sufficient sensitivity 
and specificity to be useful in a clinical setting, is suggested by our data. 
 
The mounting perception that there may be up to 100 molecular profiles in cancer has 
now sparked further studies aimed at elucidating the individual properties of tumors 
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(Koboldt D, 2012)(Tian et al, 2012)(Souchelnytskyi, 2005). Our study exemplifies 
such tactic. Our data indicate that complete profiling of individual tumors may pave 
through targeting a specific tumor in an individual patient through customized cancer 













































2.3.2 Paper 2 
 
Mammalian sterile-like 1 kinase inhibits TGFβ and EGF-dependent regulation 
of invasiveness, migration and proliferation of HEC-1-A endometrial cancer 
cells 
 
Tumorigenesis is the result of malfunction of many genes, proteins and metabolites. 
Among these molecules, TGF-β and EGF have prominent places as strong regulators 
of tumorigenesis. TGFβ pathway associate with several signaling pathways including 
epidermal growth factor (EGF) signaling pathway to modulate its effects (Dunfield & 
Nachtigal, 2003). TGF-β and EGF intracellular signaling involves sharing 
intracellular signaling mechanisms. The extensive cross-talk between TGF-β and 
EGF involves proteins and genes such as Smads, Erk1/2, p38 and PI3K; new cross-
talk components are now being explored.  
 
Mammalian Sterile-like 1 (MST1) is a serine/threonine kinase belonging to the Sterile 
20-like superfamily, and has been described to be a stress-activated protein involved 
in a various apoptotic responses (Creasy & Chernoff, 1995)(Minoo et al, 2007). 
MST1 functions as a key regulator of mammalian development, cell-cycle 
progression and tumorigenesis (Cinar et al, 2011). A loss or reduction of MST1  
expression has been suggested in head and neck squamous cell carcinoma (Steinmann 
et al, 2009), soft tissue sarcoma (Seidel et al, 2007), glioblastoma (Qiao et al, 2010), 
and colorectal cancers (Minoo et al, 2007), along with worse prognosis in cancer 
(Seidel et al, 2007). Other in vivo studies have also indicated that conditional ablation 
of MST1 resulted in liver enlargement (Song et al, 2010). Despite recent advances in 
our understanding of the role of MST1 in tumorigenesis, involvement of MST1 in 
other signaling pathways and in regulation of invasiveness of endometrial cancer cells 
remains relatively unexplored. We report here that MST1 modulates cross-talk 
between TGFβ and EGF in regulation of cell proliferation, migration and 
invasiveness. 
 
We have previously identified MST1 as a protein that is deregulated in endometrial 
cancer (Attarha et al, 2013). Network analysis suggests that MST1 may be involved 
in cross-talk between TGFβ and EGF. The involvement of MST1 may have an impact 
on cell proliferation via regulation of Ras and on cell death via regulation of caspase-
3 and p53. It should be noted that the molecular mechanisms of MST1 action are 
undergoing extensive exploration, and we may therefore expect missing interactions 
between MST1, TGFβ and EGF. Consequently, to explore the role of MST1 in 
cellular response to TGFβ1 and EGF, we used overexpression of wild-type and the 
Ser82Ala mutant of MST1 in human endometrial carcinoma cells (HEC-1-A). The 
mutant MST1 was reported to have strongly decreased phosphorylation and disrupted 
dimerization (Bi et al, 2010). Both MST1 constructs were expressed at similar levels, 
and expression was not affected by treating the cells either with TGFβ1 and EGF 
alone or in combination. This indicates that TGFβ1 and EGF did not affect the 
stability of the MST1 expressed in HEC-1-A cells. MST1-transfected cells showed no 
signs of enhanced cell death, indicating that MST1 itself under the conditions used 
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did not induce cell death. We were therefore able to use HEC-1-A cells transfected 
with wild-type and mutant MST1 for further study.  
 
First, we explored whether MST1 might affect cellular physiology and response to 
TGFβ1 and EGF in regulation of cell proliferation, apoptosis, migration and 
invasiveness. To study cell proliferation we performed MTT assay. We observed that 
TGFβ1 and/or EGF reduced the proliferation rate of cells. The inhibitory effect of 
EGF was unexpected, but also reproducible. The MST1 effect was rather marginal 
when the cells were treated with TGFβ1 or EGF alone. The wild-type MST1 inhibited 
MTT activity when expressed in non-treated cells, but this effect was not observed 
when cells were treated with TGFβ1 or EGF. The most pronounced inhibitory effect 
of combined treatment with TGFβ1 and EGF was prevented in cells expressing WT 
or mutant MST1. One interesting observation is that the MST1 mutant had an impact 
similar to that of the wild-type construct, indicating that impairment of MST1 activity 
is not essential for MST1 activity to have a negative impact on TGFβ1 and EGF 
cross-talk.   
 
One cellular mechanism affected in cancer is cell death. We therefore studied whether 
MST1 kinase affects cell apoptosis. Expression of MST1 promoted apoptosis activity 
of cells when treated with EGF and TGFβ1, while a stimulatory tendency was noted 
in non-treated cells. However, these effects were not strong, and did not affect 
cellular growth. We therefore concluded that the effect of MST1 on cell death was 
not pronounced.  
 
To explore the effects of MST1 on cell migration, we performed wound healing and 
membrane migration assays. These assays explore cells in different conditions: in a 
confluent monolayer and in a sparse culture. However, in both assays the cells are 
prompted to migrate and this migration is then measured. The wound-healing assay 
showed that expression of MST1 constructs inhibited cell migration in non-treated 
and TGFβ1 or EGF-treated cells. When cells were treated with both TGFβ1 and EGF, 
significant inhibition was observed. This inhibition was slightly counteracted by 
expression of wild-type MST1. The most pronounced effect of TGFβ1 and EGF 
treatment on cell migration was observed in a membrane migration assay. We 
observed that combined treatment with TGFβ1 and EGF strongly induced cell 
migration, while treatment with either alone had only a marginal effect.  Expression 
of both MST1 constructs resulted in much lower cell migration. Interestingly, the 
ability of MST1 to dimerize was not important for this inhibitory effect. Another 
conclusion is that cells in a dense monolayer may respond differently to stimulation 
of migration than cells in a sparse culture.  
 
Cell invasiveness is an important characteristic for tumorigenesis. We explored 
invasiveness of cells through a layer of denatured collagen (gelatin). We observed 
that transfection of MST1 constructs enhanced cell invasiveness, although the level of 
induction varied with different treatment conditions. The strongest stimulatory effect 
was observed with expression of mutant MST1 in non-treated cells. This stimulatory 
effect disappeared when cells were treated with TGFβ1 and/or EGF. We observed 
that combined treatment of cells with TGFβ and EGF decreased invasiveness when 
MST1 constructs were expressed. This observation indicates that abrogation of 
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dimerization and subsequent inhibition of the kinase activity of MST1 was not 
essential when cells were treated, but were important for response of non-treated 
cells. Thus, MST1 constructs counteracted the stimulatory effect of combined 
treatment with TGFβ1 and EGF on cell invasiveness. 
 
TGFβ and EGF employ many different signal transducers, with convergence on many 
common targets. To explore at what level of the signal transduction MST1 may 
interfere with TGFβ and EGF signaling, we measured expression and/or activation of 
Smad2, pRb, FAK and Erk1/2, as well as expression of vimentin and E-cadherin.  
 
Phosphorylation of Smad2 at its C-terminal serine residues reflects activation of 
signaling downstream of TGFβ receptors (Souchelnytskyi et al, 1997). We observed 
that only expression of wild-type MST1 had a significant inhibitory effect on 
expression of Smad2 and Smad3, and phosphorylation of Smad2. Under all other 
conditions, variations were less pronounced. This indicates that MST1 does not affect 
proximal TGFβ signaling events via Smad2 protein.  
 
We observed no significant effect of MST1 on pRb expression nor its 
phosphorylation on Serine 780 residue. This observation is not in line with the results 
of the MTT proliferation assay, and suggests that pRb expression and Ser780 
phosphorylation do not correlate with MST1 impact. Phosphorylation of Erk1/2 
kinase often correlates with cellular proliferation rate. As in the case of pRb, we see 
no correlation between Erk1/2 phosphorylation and the results of the proliferation 
assay. However, we observed that expression of MST1 constructs did modulate 
Erk1/2 phosphorylation when treated with TGFβ1 and/or EGF, suggesting that Erk1/2 
phosphorylation is modulated by MST1, but its impact on cell physiology remains to 
be elucidated. At least the impact is not reflected in the cellular proliferation rate. 
 
Phosphorylation and expression of focal adhesion kinase (FAK) allows monitoring of 
cytoskeleton rearrangements involved in cell migration. We observed that FAK 
phosphorylation correlated with enhanced invasiveness of HEC-1-A cells, whether 
transfected or not, that were treated with different combinations of TGFβ1 and EGF. 
For migration assay results, correlation was observed for all conditions, except among 
non-transfected cells, which showed high phosphorylation of FAK, while no 
migration through the membrane was observed.  
 
E-cadherin and vimentin are markers of the epithelial-mesenchymal phenotype of 
cells. They are also used as markers to evaluate invasiveness-related epithelial-
mesenchymal transition (EMT). HEC-1-A cells show detectable expression levels of 
vimentin and E-cadherin.  Expression of either of the MST1 constructs did not 
modulate vimentin expression, while expression of the wild-type MST1 reduced E-
cadherin levels following single TGFβ1 and double TGFβ1 and EGF treatments. 
TGFβ-dependent inhibition of E-cadherin expression is known to be a part of TGFβ-
induced EMT. The results of immunoblotting for E-cadherin indicate that MST1 has 
modulatory impact on TGFβ and/or EGF regulated expression of E-cadherin, but this 
impact must be combined with other regulatory processes, which then would result in 
impact on cell proliferation, migration and invasiveness. Among the markers of 
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intracellular signaling pathways that we evaluated, phosphorylation of FAK showed 
good correlation with a pattern of cellular invasiveness.   
 
 Cellular functions are controlled by combinations of different regulators. Here we 
described the impact of MST1 on functional interaction between TGFβ and EGF in 
the regulation of cell invasiveness, migration and proliferation. Recent studies 
showed that MST1 regulates cell death, differentiation and proliferation (Qin et al, 
2013). Aberrations in MST1 expression have been observed in tumorigenesis, with 
indications that MST1 may have a tumor suppressive role (Ng et al, 2013)(Minoo et 
al, 2007). Many laboratories are currently investigating MST1 intracellular signaling 
mechanisms; one key conclusion is that MST1 may play the role of coordinator 
between different pathways.  
 
EGF and TGFβ are two well-studied regulators of tumorigenesis. EGF is 
predominantly a tumor-promoting factor, presumably due to its strong pro-mitogenic 
activity (Scaltriti & Baselga, 2006). In contrast, TGFβ is a strong inhibitor of 
epithelial cell proliferation. However, TGFβ has a dual role in tumorigenesis 
(Katsuno et al, 2013a)(Massagué, 2012). In the early stages, it prevents tumor 
growth, while in later stages of cancer it stimulates metastasis. Extensive cross-talk 
between EGF and TGFβ has been described. Intracellular regulators that were first 
considered to be specific to TGFβ or EGF pathways, were later shown to be shared 
between these pathways (Katsuno et al, 2013a)(Massagué, 2012). 
 
The identification of MST1 as a protein with potential involvement in the cross-talk 
between TGFβ and EGF prompted us to explore whether MST1 can indeed affect 
EGF and TGFβ-dependent regulation of cell invasiveness, migration and 
proliferation. MST1 has been reported to induce cell death (Graves et al, 1998)(Qiao 
et al, 2010)(Lin et al, 2002). We observed only marginal cell death induction with 
transfection of wild-type MST1 in HEC-1-A cells. Our results showed that MST1 
may act as a negative regulator of the combined action of TGFβ and EGF on cell 
invasiveness and migration, while it has no pronounced effect when cells are 
challenged with each of the growth factors independently. This observation 
underscores the importance of exploring combination treatments. The challenge of 
such exploration lies in the high number of intracellular regulators that would need to 
be tested. We monitored some of the proteins that may be involved in activation of 
TGFβ and EGF signaling (Smad2 and Erk1/2) and other proteins that may reflect 
migratory and invasive mechanisms (FAK, vimentin and E-cadherin). The 
exploration of cellular responses to the combination of TGFβ, EGF and MST1, along 
with the evaluation of protein markers of signaling pathways reported here, provide 
incentive for additional, more detailed mechanistic studies. Our data also include 
MST1 in the network of TGFβ and EGF signaling, which may also help improve 
prediction of responses to drugs currently in use or in clinical trials that target EGF 






2.3.3 Paper 3  
 
PKN1 modulates TGF-β and EGF signaling in HEC-1-A endometrial cancer cell 
line  
 
Protein kinase N1 (PKN1), also known as PAK1 is a serine/threonine kinase involved 
in formation of mammary gland tumors and premalignant lesions in animal models, 
albeit with long latency (Ong et al, 2011). PKN1 overexpression has been reported to 
have an association with prostate, colorectal and aggressive ovarian cancers (Carter et 
al, 2004)(Metzger et al, 2003)(Galgano et al, 2009). Further studies suggested, PKN1 
may also influence the invasive characteristics of breast and gastric cancer cells 
(Adam et al, 2000)(Liu et al, 2009). 
 
PKN1 contains three highly conserved regions: (i) a regulatory domain in the N 
terminal (ii) a catalytically active part located in the C terminal similar to protein 
kinase C (PKC) (iii) an area referred to as the D region located between the 
regulatory and catalytic domains (Metzger et al, 2003)(Takahashi et al, 1998). The N-
terminal domain function is crucial for activation of PKN1 (Takahashi et al, 1998) by 
providing the PKN1 activation loop, which is important for serine/threonine kinase 
activity and the regions required for interaction with other factors participating in the 
signaling pathway of PKN1, such as Ro GTPases that bind to the hydrophobic region 
of PKN1 in the N-terminal (Galgano et al, 2009). Once activated, PKN1 facilitates 
downstream signaling actions involved in apoptosis, transformation, cell motility and 
reorganization of the cytoskeleton. PKN1 also activates various signaling pathways, 
as well as p38 MAPK, JNK, NF-kB and ERKs (Vadlamudi et al, 2000). 
 
Transforming growth factor-β (TGFβ) was found to have a dual role in tumorigenesis. 
In early-stage cancer, TGFβ has a tumor suppressor role that results in growth 
inhibition, cell cycle arrest, and apoptosis. Meanwhile, in advance-stage cancer, 
TGFβ promotes tumorigenesis. The cancer cells may lose responsiveness to TGFβ 
and may acquire aberrant TGFβ signaling, followed by promotion of survival, 
proliferation and EMT, as well as increased cell motility and invasiveness (Jakowlew, 
2006). TGFβ pathway associate with several signaling pathways including epidermal 
growth factor (EGF) signaling pathway to modulate its effects (Dunfield & Nachtigal, 
2003).  EGF is a key regulator of various cellular functions which principally plays a 
role of a pro-mitogenic molecule in carcinogenesis (Scaltriti & Baselga, 2006). EGF 
also promotes cell survival, angiogenesis and differentiation. Deregulation of EGF 
pathways promote tumorigenesis through constitutive activation or overexpression of 
EGF signaling and is along with a worse prognosis in numerous human malignancies 
(Lurje & Lenz, 2009).  
 
Signaling cross-talk between different regulators is of key importance for 
tumorigenesis. The cross-talk may explain modulation of cellular responses to the 
same regulator by another signaling molecule. Since PKN1 was identified as a 
potential cross-talk node for TGFβ and EGF signaling, we explored what cellular 
functions might be affected by PKN1 in cross-talk with TGFβ and EGF. Here we 
report that PKN1 modulates TGFβ and EGF-dependent regulation of cell 
 35 
 
proliferation, migration and invasiveness, and is therefore a component of the 
network signaling downstream of TGFβ and EGF. 
 
We identified PKN1 as a protein that is deregulated in endometrial cancer (Attarha et 
al, 2013). To study the impact of PKN1 on cells, we transiently expressed wild-type, 
kinase-negative and constitutively active PKN1 in HEC-1-A endometrial cancer cells. 
Expression of PKN1 was controlled by immunoblotting with anti-PKN1 antibody. 
We observed expression of endogenous PKN1 in 6 out 7 tested cell lines. Enhanced 
expression of PKN1 constructs allowed us to accentuate the impact of PKN1 on cell 
physiology. Transiently transfected cells were then used in tests described below. 
Systemic analysis of potential connections between PKN1, TGFβ and EGF showed 
involvement of a number of potent regulators of cell proliferation and cytoskeleton 
rearrangement, which prompted us to explore whether PKN1 plays a role in 
modulation of TGFβ and EGF-dependent regulation of cell proliferation, migration 
and invasiveness.  
 
We observed that the treatment of cells with TGFβ1 and EGF significantly reduced 
the proliferation rate of control parental empty vector transfected and wild-type (WT) 
PKN1 transfected HEC-1-A cells. Transfection of HEC-1-A cells with kinase-
inactive (KN) PKN1 and constitutively active (CA) PKN1 resulted in a reduced rate 
of proliferation of the non-treated cells. We observed that expression of KN PKN1 
countered the effects of TGFβ1 and EGF. One unexpected effect was that CA PKN1 
countered the effects of EGF and combined TGFβ1 and EGF treatments. The 
observation with the CA mutant of PKN1 indicates that truncation of PKN1 has a 
similar impact on the PKN1 contribution as does the KN construct. It also indicates 
that kinase activity itself is not sufficient to mimic WT PKN1, and PKN1 must be 
intact to be fully functional. Thus, PKN1 is required for inhibition of cell proliferation 
through the combined action of TGFβ1 and EGF, since impairment of PKN1 function 
by blocking the kinase activity or by truncation prevents the inhibitory effect of 
TGFβ1 and EGF. 
 
To explore whether PKN1 affects cell death, we performed an apoptosis assay. We 
observed that dual treatment of the empty vector-transfected cells with TGFβ1 and 
EGF reduced cell apoptosis. Transfection of WT, KN or CA constructs of PKN1 had 
only a marginal effect on cell death. The only significant, albeit weak, effect was 
reversal of the effect of combined treatment with TGFβ1 and EGF. We did not 
observe the presence of apoptotic cells or apoptotic bodies upon visual inspection of 
transfected and treated cells. Consequently, we observed no strong effects of PKN1 
on cell death that could influence cell response to TGFβ1 and EGF in our study.        
 
Since our systemic analysis indicated that PKN1 may affect migration of cells, we 
performed wound healing (Liang et al, 2007) and membrane migration (Penno et al, 
1997) assays. The wound healing assay explores migration capacities of cells, which 
are under contact inhibition of proliferation. The membrane migration assay explores 
proliferating cells in a sparse culture. The molecular mechanisms triggering cell 
migration in these two tests may differ since the conditions to which the cells are 
subjected are not equivalent. Despite these differences, the tests may complement 
each other to allow assessment of migration. The wound healing assay showed that 
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PKN1 constructs prevented TGFβ1-induced closure. However expression of PKN1 
constructs strongly promoted wound closure when cells were treated with both 
TGFβ1 and EGF.  
 
The membrane migration assay showed that treatment with both TGFβ1 and EGF 
promoted cell migration. Single treatments and transfections with PKN1 constructs 
did not have any significant effects. The difference in response pattern between 
wound healing and membrane migration is that impairment of PKN1 activity in KN 
and CA mutants did not mimic the WT construct effect seen in the membrane 
migration assay, compared with the wound healing tests. Despite this difference, our 
results show that PKN1 may indeed counteract the action of combined treatment of 
cells with TGFβ1 and EGF. 
 
Invasiveness of cells into a collagen matrix is one of the key mechanisms involved in 
metastasis. We explored whether PKN1 constructs could affect TGFβ1 and EGF-
dependent regulation of cell invasiveness. We observed that treatment of HEC-1-A 
cells with both TGFβ1 and EGF together increased invasiveness of cells transfected 
with the KN construct of PKN1, while expression of WT or CA constructs of PKN1 
did not have this effect. Expression of KN PKN1 significantly increased cell 
invasiveness. This stimulatory effect was strong. Thus, PKN1 did modulate 
invasiveness of cells, with apparently different intracellular mechanisms than those 
involved in regulation of cell migration.   
 
To explore molecular mechanisms of PKN1 involvement in TGFβ and EGF 
signaling, we studied expression and phosphorylation of Smad2, Erk1/2, FAK, E-
cadherin and vimentin.  
 
Phosphorylation of Smad2 and Erk1/2 reflects activation of signaling downstream of 
TGFβ and EGF. We observed that expression of WT, KN and CA PKN1 decreased 
the intensity of Smad2 phosphorylation when treated with TGFβ1. The effect was 
more significant in CA PKN1 transfected cells.  At the same time, phosphorylation of 
Smad2 decreased in KN and CA PKN1 transfected cells when treated with a 
combination of TGFβ1 and EGF, or EGF alone, while no change was seen in WT 
PKN1 transfected cells. We observed that expression of WT, KN and CA PKN1 
decreased the intensity of Erk1/2 phosphorylation when treated with TGFβ1. We 
observed that EGF-dependent Erk1/2 phosphorylation increased in WT, KN and CA 
PKN1-transfected cells, but not in the vector-transfected cells, indicating that the cells 
were responsive to EGF when subjected to the enhanced level of PKN1. The effect 
was most pronounced in KN-transfected cells. Dual treatment of cells with TGFβ1 
and EGF had no significant effect on intensity of Erk1/2 phosphorylation in WT and 
KN transfected cells, while it caused a significant decrease in HEC-1-A CA PKN1 
cells.  
 
Expression and activity of focal adhesion kinase (FAK), E-cadherin and vimentin 
may reflect molecular mechanisms involved in regulation of cell migration and 
invasiveness. We observed that expression of the WT PKN1 construct increased 
TGFβ1 and EGF-dependent phosphorylation of FAK, while KN PKN1 expression 




We observed that expression of WT and CA PKN1 predominantly inhibited             
E-cadherin expression when subjected to either single or dual treatment with TGFβ1 
and EGF. The KN construct of PKN1 did not have such an inhibitory effect. 
Vimentin expression under test conditions was not modulated by treatment with 
TGFβ1 and/or EGF. The only observed effect involved WT and KN PKN1, which 
inhibited vimentin levels regardless of treatments. The observations of changes in E-
cadherin, vimentin, Smad2 and Erk1/2 expression and phosphorylation indicate that 
these proteins are indeed affected by PKN1. Our observations justify further studies 
of the tested proteins in regard to the role of PKN1 in proliferation, migration and 
invasiveness to gain insight into the underlying molecular mechanisms.   
 
Unraveling the complexity of intracellular signaling cross-talk results in identification 
of more and more components and interactions between them. Systems biology tools 
now allow us to identify potential interactions between proteins and genes, which 
otherwise might remain undetected. Our search for the mechanisms underlying cross-
talk between TGFβ and EGF indicate that PKN1 may be a convergence point for 
these two potent regulatory pathways (Attarha et al, 2013). We found that PKN1 is 
involved as a modulator of cross-talk between TGFβ and EGF in regulation of cell 
proliferation, migration and invasiveness. The modulating effects of PKN1 were 
dependent on its kinase activity. The description of cellular responses shows 
involvement of PKN1 in TGFβ and EGF signaling. The exact molecular mechanisms 
underlying this cross-talk require further detailed study. Our data indicate that Smad2 
and Erk1/2 may be involved in the cross-talk. Smad2 is a direct target of TGFβ 
receptor type I and Erk1/2 is a convergence target of many different regulators of cell 
proliferation. It has been shown that Smad2 can be phosphorylated by Erk1/2, and 
that phosphorylation may inhibit nuclear localization of Smad2 (Kamato et al, 2013). 
Focal adhesion may be regulated by multiple factors, and our results show that PKN1 
may interfere with TGFβ- and EGF-dependent phosphorylation of FAK. The effects 
on FAK phosphorylation are in line with PKN1 modulation of cell invasion and 
migration. Expression of vimentin and E-cadherin under the explored conditions is 
also in line with cellular response. It must be noted that the observed correlations 
indicate involvement of other intracellular components, since the types and 
amplitudes of changes did not fully overlap with cellular responses. Our systemic 
analysis and numerous reports by others show that more than 100 molecules may be 
involved in network signaling by TGFβ and EGF (Katsuno et al, 2013b)(Ghosh et al, 
2011). These molecules are involved in different stages of the signaling cascades, and 
may include various intracellular processes, such as gene transcription, protein 
synthesis, protein activities, localization, and metabolic processes. These intracellular 
processes then exert influence on regulators of cellular responses. Our report includes 
PKN1 in this network of combined signaling by TGFβ and EGF, which leads to 
regulation of cell migration, invasiveness and proliferation, and provides direction for 








3 General conclusions  
 
The results of studies presented here are expected to contribute to better 
understanding of the mechanisms underlying human endometrial tumorigenesis, 
development of novel targets for anticancer treatments, and identification of tumor 
signatures and prognostic markers for diagnostics and monitoring of endometrial 
cancer: 
 
 Profiling of individual tumors of EC patients opens up the prospect of treating 
the specific tumor of an individual patient with tumor-specific cancer drugs. 
Systemic analysis of individual proteome profiles represented that different 
proteins may be impacted in the individual endometrial tumors of different 
patients, but the impact of these proteins on basic cell functions may still be 
similar. Incorporation of gene expression data sets of profiling of endometrial 
tumors and our proteome profiling supports the conclusion that individual tumor 
features are doubtlessly crucial in endometrial tumorigenesis and are not 
inconsistent individual variations. The potential of PKN1 and MST1 to serve as 
potential predictive biomarkers of EC, with sufficient sensitivity and specificity 
to be useful in a clinical setting, is suggested by our data. 
 
 MST1 may act as a negative regulator of the combined action of TGFβ and EGF 
on cell proliferation, invasiveness and migration of HEC-1-A endometrial cancer 
cells, while this effect is significantly less pronounced when cells are challenged 
with each growth factor separately. Monitoring of the intracellular regulatory 
proteins showed that the MST1 contribution to TGFβ-EGF cross-talk may 
involve focal adhesion kinase and E-cadherin, but not activation of Smad2. 
These observations underscore the importance of exploring combination 
treatments. 
 
 Analysis of PKN1 involvement in the cellular regulatory processes indicated its 
role as a point of convergence for TGF-β and EGF initiated signaling which has 
inhibitory effect on stimulation of cell migration and that its kinase activity was 
required for the inhibitory effect on cell proliferation and invasiveness. 
Monitoring of the intracellular regulatory proteins showed that phosphorylation 
of Smad2, FAK and Erk1/2 correlated with cellular response to TGFβ1 and EGF. 




Despite identification of numerous EC-associated proteins, our knowledge of 
proteomics analysis of endometrial carcinoma is poorly developed. Lack of 
commonly used biomarkers in routine clinical practice for detection of early stage or 
aggressive EC promoted us to perform such analysis which expected to provide 
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